miR-198在治疗和诊断皮肤鳞状细胞癌中的用途

本发明涉及通过施用一种或多种包含miR-198的序列(SEQ ID NO:1)或其功能部分的寡核苷酸或降低卵泡抑素相关蛋白1(FSTL1)、蛋白质透明同源物1(DIAPH1)、层粘连蛋白亚基γ-2(LAMC2)或尿激酶型纤溶酶原激活物(PLAU)表达的寡核苷酸来治疗癌的方法。优选地，针对FSTL1、DIAPH1、LAMC2或PLAU的至少一种或多种寡核苷酸是shRNA或siRNA。还提供了确定受试者中癌的存在的方法，其包括检测和比较miR-198和/或FSTL1、DIAPH1、LAMC2或PLAU、miR-181a、表皮生长因子(EGF)和表皮生长因子受体(EGFR)中的至少一种的存在，并将检...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageChinese
Published 07.06.2022
Subjects
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TESTING
Online AccessGet full text

Cover

More Information
Summary:本发明涉及通过施用一种或多种包含miR-198的序列(SEQ ID NO:1)或其功能部分的寡核苷酸或降低卵泡抑素相关蛋白1(FSTL1)、蛋白质透明同源物1(DIAPH1)、层粘连蛋白亚基γ-2(LAMC2)或尿激酶型纤溶酶原激活物(PLAU)表达的寡核苷酸来治疗癌的方法。优选地，针对FSTL1、DIAPH1、LAMC2或PLAU的至少一种或多种寡核苷酸是shRNA或siRNA。还提供了确定受试者中癌的存在的方法，其包括检测和比较miR-198和/或FSTL1、DIAPH1、LAMC2或PLAU、miR-181a、表皮生长因子(EGF)和表皮生长因子受体(EGFR)中的至少一种的存在，并将检测到的水平与对照样品中的水平进行比较。 The present invention refers to a method of treating a carcinoma by administration of one or more of an oligonucleotide comprising the sequence of miR-198 (SEQ ID NO: 1) or a functional part thereof, or an oligonucleotide which reduces expression of Follistatin-related protein 1 (FSTL1), Protein diaphanous homolog 1 (DIAPH1), Laminin subunit gamma-2 (LAMC2) or Urokinase-type plasminogen activator (PLAU). Preferably, the at least one or more oligonucleotides directed against FSTL1, DIAPH1, LAMC2 or PLAU is a shRNA or siRNA. Also provided is a method of determining the presence of carcinoma in a subject, comprising detecting and comparing the presence of miR-198 and/or at least one of FSTL1, DIAPH
Bibliography:Application Number: CN201780049544